Brief: AB Science Says It Has Filed Application For Conditional Marketing Authorization To EMA For Masitinib
24/08/2022 18:10
Aug 24 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCES THAT IT HAS FILED AN APPLICATION FOR
CONDITIONAL MARKETING AUTHORIZATION TO EMA FOR MASITINIB IN THE
TREATMENT OF ALS
* THIS APPLICATION HAS NOW BEEN VALIDATED BY EMA AND REVIEW
BY
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS BEGUN
* CHMP HAS A TARGET OF 210 ACTIVE EVALUATION DAYS TO REVIEW
APPLICATION
Source text for Eikon: ID:nGNE7q7ZXc
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041